August, 2017—Health care venture capitalist Jonathan Silverstein has more than two decades of professional experience with strategic investment in drug development. However, Jonathan’s sense of urgency to find cures intensified after he received a diagnosis...
August, 2017—The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO Inc. (“REGENXBIO”), and OrbiMed today announced the formation and launch of Prevail Therapeutics, Inc., (“Prevail”), a new company focused on discovering and developing novel biologic...
August, 2017—Regenxbio has joined forces with investment firm OrbiMed and a new nonprofit foundation to create Prevail Therapeutics, a startup focused on new biologics and gene therapies for Parkinson’s disease (PD).
August, 2017—Wall Street investor Jonathan Silverstein has spent a career finding and funding biotech firms working on cures for rare diseases. But after learning in February he has Parkinson’s Disease, the diagnosis set him and his wife on a path to create a...
August, 2017—It’s been less than a year since Jonathan Silverstein, a venture capitalist at health-care fund OrbiMed, received the diagnosis that changed everything.
